7NLL

SARS-CoV-2 Spike RBD (dimer) in complex with two Fu2 nanobodies

7NLL の概要

• エントリーDOI: 10.2210/pdb7nll/pdb
• EMDBエントリー: 12465
• 分子名称: Spike protein S1, Nanobody Fu2, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
• 機能のキーワード: nanobody, spike, complex, dimer, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2; 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 83448.60

構造登録者

Das, H.,Hallberg, B.M. (登録日: 2021-02-22, 公開日: 2022-02-02, 最終更新日: 2024-11-13)

主引用文献

Hanke, L.,Das, H.,Sheward, D.J.,Perez Vidakovics, L.,Urgard, E.,Moliner-Morro, A.,Kim, C.,Karl, V.,Pankow, A.,Smith, N.L.,Porebski, B.,Fernandez-Capetillo, O.,Sezgin, E.,Pedersen, G.K.,Coquet, J.M.,Hallberg, B.M.,Murrell, B.,McInerney, G.M.
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
Nat Commun, 13:155-155, 2022

PubMed Abstract: Antibodies binding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike have therapeutic promise, but emerging variants show the potential for virus escape. This emphasizes the need for therapeutic molecules with distinct and novel neutralization mechanisms. Here we describe the isolation of a nanobody that interacts simultaneously with two RBDs from different spike trimers of SARS-CoV-2, rapidly inducing the formation of spike trimer-dimers leading to the loss of their ability to attach to the host cell receptor, ACE2. We show that this nanobody potently neutralizes SARS-CoV-2, including the beta and delta variants, and cross-neutralizes SARS-CoV. Furthermore, we demonstrate the therapeutic potential of the nanobody against SARS-CoV-2 and the beta variant in a human ACE2 transgenic mouse model. This naturally elicited bispecific monomeric nanobody establishes an uncommon strategy for potent inactivation of viral antigens and represents a promising antiviral against emerging SARS-CoV-2 variants.

PubMed: 35013189
DOI: 10.1038/s41467-021-27610-z

実験手法

ELECTRON MICROSCOPY (2.89 Å)